Pulse Biosciences, Inc., a development stage medical device company, focuses on developing medical technologies based on sub-microsecond pulsed electric field technology to detect and treat skin cancer and enhance wound healing. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is based in Burlingame, California.
News: Pulse Biosciences advanced 17.19% to close at $30.34 on Friday. The stock traded between a high of $30.61 and low of $25.62 on volume of 760,447 shares traded. The advance was in part stimulated by news that there is a development of a drug that will be compatible with their recently submitted 510(k) device application to the FDA. Pulse Biosciences submitted a 510(k) application to the FDA for its PulseTx(TM) System. Darrin Uecker, CEO and President of Pulse Biosciences said, "The submission is an important step to improve healthcare by delivering our unique technology to both physicians and their patients." At the end of the reporting period of December 31, 2016, the company had cash, cash equivalents and investments totaling $16.4 million and the company has reported a loss of $0.21 a share and $0.86 a share for the fourth quarter and full year of 2016 respectively.
